CNBC: The State of Pharma in 2022

2022 has been a tumultuous year for pharma and biotech, with shifting market conditions, the Russian invasion of Ukraine, and US policy changes that spell an uncertain for the industry over the next few years. A newly published article by Ekta Batra reviews how the pharma industry performed in 2022, for better or worse.

According to Batra, “For the US, an important development was a clutch of Indian companies such as Natco, Dr Reddy’s and Cipla launching the generic version of blockbuster cancer drug Revlimid generic. Challenges included fierce price pressure in the US continuing with the likes of Lupin exiting certain drugs and Aurobindo delaying its injectable sales guidance of $650 million to $700 million to financial year 2025. It was also a patchy year for USFDA inspections with problems continuing for the likes of Sun’s Halol facility, Cipla’s Goa plant, Glenmark’s Baddi plant.”

To read more, click here.

(Source: CNBC TV 18, December 27^th, 2022)